Snap Inc. Stock Underperforms Tuesday When Compared To Competitors

TetraLogic Pharmaceuticals Corp

Change company Symbol lookup

Select an option...

TLOG TetraLogic Pharmaceuticals Corp

JPM-K JPMorgan Chase & Co

KLAC KLA Corp

CNVY Convey Health Solutions Holdings Inc

EBAY eBay Inc

PRLX Parallax Health Sciences Inc

AXS AXIS Capital Holdings Ltd

SPNS Sapiens International Corporation NV

SPCE Virgin Galactic Holdings Inc

BBLG Bone Biologics Corp

Company profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Snap Inc. Stock Underperforms Tuesday When Compared To Competitors

5:21 pm ET June 28, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Snap Inc. SNAP shed 5.70% to $13.73 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index COMP falling 2.98% to 11,181.54 and Dow Jones Industrial Average DJIA falling 1.56% to 30,946.99. This was the stock's second consecutive day of losses. Snap Inc. closed $69.61 short of its 52-week high ($83.34), which the company achieved on September 24th.

The stock underperformed when compared to some of its competitors Tuesday, as Apple Inc. AAPL fell 2.98% to $137.44 and Twitter Inc. TWTR fell 1.02% to $38.79. Trading volume (24.4 M) remained 24.4 million below its 50-day average volume of 48.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled June 28, 2022.

(END) Dow Jones Newswires

June 28, 2022 17:21 ET (21:21 GMT)